{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:17:23Z","timestamp":1775477843741,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["994"],"award-info":[{"award-number":["994"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biotechnol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s12033-023-00700-7","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T17:02:40Z","timestamp":1678554160000},"page":"1968-1978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and Characterization of a Novel Single-Chain Antibody Against B-Cell Activating Factor"],"prefix":"10.1007","volume":"65","author":[{"given":"Rasoul","family":"Mardani-Jouneghani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Habibi-Anbouhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4839-5123","authenticated-orcid":false,"given":"Mahdi","family":"Behdani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"issue":"Suppl. 5","key":"700_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1289\/ehp.99107s5661","volume":"107","author":"D Smith","year":"1999","unstructured":"Smith, D., & Germolec, D. (1999). Introduction to immunology and autoimmunity. Enviromental Health Perspectives, 107(Suppl. 5), 661\u2013665. https:\/\/doi.org\/10.1289\/ehp.99107s5661","journal-title":"Enviromental Health Perspectives"},{"key":"700_CR2","first-page":"51","volume":"3","author":"SP Singh","year":"2016","unstructured":"Singh, S. P., Wal, P., Wal, A., Srivastava, V., Tiwari, R., & Sharma, R. D. (2016). Understanding autoimmune disease: An update review. IJPTB, 3, 51\u201365.","journal-title":"IJPTB"},{"issue":"4","key":"700_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang, L., Wang, F. S., & Gershwin, M. E. (2015). Human autoimmune diseases: A comprehensive update. Journal of Internal Medicine, 278(4), 369\u2013395.","journal-title":"Journal of Internal Medicine"},{"issue":"5517","key":"700_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495\u20137.","journal-title":"Nature"},{"key":"700_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/BF03258506","volume":"1","author":"E Racadot","year":"1994","unstructured":"Racadot, E., Wendling, D., Rumbach, L., Wijdenes, J., & Herve, P. (1994). Current concepts in the treatment of autoimmune diseases with monoclonal antibodies. Clinical Immunotherapeutics, 1, 199\u2013208.","journal-title":"Clinical Immunotherapeutics"},{"issue":"11","key":"700_CR6","doi-asserted-by":"publisher","first-page":"102390","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux, Y., El Jammal, T., Vuitton, L., Gerfaud-Valentin, M., Kerever, S., & S\u00e8ve, P. (2019). JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews, 18(11), 102390.","journal-title":"Autoimmunity Reviews"},{"issue":"7","key":"700_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nri844","volume":"2","author":"F Mackay","year":"2002","unstructured":"Mackay, F., & Browning, J. L. (2002). BAFF: A fundamental survival factor for B cells. Nature Reviews Immunology, 2(7), 465\u2013475.","journal-title":"Nature Reviews Immunology"},{"issue":"6","key":"700_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrrheum.2014.33","volume":"10","author":"FB Vincent","year":"2014","unstructured":"Vincent, F. B., Morand, E. F., Schneider, P., & Mackay, F. (2014). The BAFF\/APRIL system in SLE pathogenesis. Nature Reviews Rheumatology, 10(6), 365\u2013373.","journal-title":"Nature Reviews Rheumatology"},{"issue":"11","key":"700_CR9","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider, P., MacKay, F., Steiner, V., Hofmann, K., Bodmer, J.-L., Holler, N., et al. (1999). BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. The Journal of Experimental Medicine, 189(11), 1747\u20131756.","journal-title":"The Journal of Experimental Medicine"},{"issue":"6","key":"700_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.coi.2010.09.010","volume":"22","author":"A Davidson","year":"2010","unstructured":"Davidson, A. (2010). Targeting BAFF in autoimmunity. Current Opinion in Immunology, 22(6), 732\u2013739.","journal-title":"Current Opinion in Immunology"},{"issue":"1","key":"700_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/eji.200636623","volume":"37","author":"D Sakurai","year":"2007","unstructured":"Sakurai, D., Kanno, Y., Hase, H., Kojima, H., Okumura, K., & Kobata, T. (2007). TACI attenuates antibody production costimulated by BAFF-R and CD40. European Journal of Immunology, 37(1), 110\u2013118.","journal-title":"European Journal of Immunology"},{"issue":"12","key":"700_CR12","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/ni.1666","volume":"9","author":"JE Stadanlick","year":"2008","unstructured":"Stadanlick, J. E., Kaileh, M., Karnell, F. G., Scholz, J. L., Miller, J. P., Quinn Iii, W. J., et al. (2008). Tonic B cell antigen receptor signals supply an NF-\u03baB substrate for prosurvival BLyS signaling. Nature Immunology, 9(12), 1379\u20131387.","journal-title":"Nature Immunology"},{"issue":"1","key":"700_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-065X.2011.01067.x","volume":"244","author":"RC Rickert","year":"2011","unstructured":"Rickert, R. C., Jellusova, J., & Miletic, A. V. (2011). Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunological Reviews, 244(1), 115\u2013133.","journal-title":"Immunological Reviews"},{"issue":"3\u20134","key":"700_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cytogfr.2008.04.006","volume":"19","author":"F Mackay","year":"2008","unstructured":"Mackay, F., & Schneider, P. (2008). TACI, an enigmatic BAFF\/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine & Growth Factor Reviews, 19(3\u20134), 263\u2013276.","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"2","key":"700_CR15","doi-asserted-by":"publisher","first-page":"e282-e","DOI":"10.1038\/bcj.2015.3","volume":"5","author":"P Hengeveld","year":"2015","unstructured":"Hengeveld, P., & Kersten, M. (2015). B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy? Blood Cancer Journal, 5(2), e282-e.","journal-title":"Blood Cancer Journal"},{"key":"700_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/792187","author":"M Rihacek","year":"2015","unstructured":"Rihacek, M., Bienertova-Vasku, J., Valik, D., Sterba, J., Pilatova, K., & Zdrazilova-Dubska, L. (2015). B-cell activating factor as a cancer biomarker and its implications in cancer-related cachexia. BioMed Research International. https:\/\/doi.org\/10.1155\/2015\/792187","journal-title":"BioMed Research International"},{"key":"700_CR17","first-page":"121","volume":"7","author":"J Manetta","year":"2014","unstructured":"Manetta, J., Bina, H., Ryan, P., Fox, N., Witcher, D. R., & Kikly, K. (2014). Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. Journal of inflammation research, 7, 121.","journal-title":"Journal of inflammation research"},{"issue":"9","key":"700_CR18","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.yexcr.2011.02.005","volume":"317","author":"Z Liu","year":"2011","unstructured":"Liu, Z., & Davidson, A. (2011). BAFF inhibition: A new class of drugs for the treatment of autoimmunity. Experimental Cell Research, 317(9), 1270\u20131277.","journal-title":"Experimental Cell Research"},{"issue":"5","key":"700_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nri2761","volume":"10","author":"AC Chan","year":"2010","unstructured":"Chan, A. C., & Carter, P. J. (2010). Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology, 10(5), 301\u2013316.","journal-title":"Nature Reviews Immunology"},{"issue":"2","key":"700_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574884712666170809124728","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh, S., Tank, N. K., Dwiwedi, P., Charan, J., Kaur, R., Sidhu, P., et al. (2018). Monoclonal antibodies: A review. Current Clinical Pharmacology, 13(2), 85\u201399.","journal-title":"Current Clinical Pharmacology"},{"issue":"40","key":"700_CR21","doi-asserted-by":"publisher","first-page":"14701","DOI":"10.1073\/pnas.0606631103","volume":"103","author":"A Giritch","year":"2006","unstructured":"Giritch, A., Marillonnet, S., Engler, C., van Eldik, G., Botterman, J., Klimyuk, V., et al. (2006). Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proceedings of the National Academy of Sciences, 103(40), 14701\u201314706.","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"700_CR22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2174\/0929867324666170817152554","volume":"26","author":"RV Kholodenko","year":"2019","unstructured":"Kholodenko, R. V., Kalinovsky, D. V., Doronin, I. I., Ponomarev, E. D., & Kholodenko, I. V. (2019). Antibody fragments as potential biopharmaceuticals for cancer therapy: Success and limitations. Current Medicinal Chemistry, 26(3), 396\u2013426.","journal-title":"Current Medicinal Chemistry"},{"issue":"14","key":"700_CR23","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1016\/j.molimm.2008.06.005","volume":"45","author":"PJ Doyle","year":"2008","unstructured":"Doyle, P. J., Arbabi-Ghahroudi, M., Gaudette, N., Furzer, G., Savard, M. E., Gleddie, S., et al. (2008). Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol. Molecular Immunology, 45(14), 3703\u20133713.","journal-title":"Molecular Immunology"},{"issue":"3","key":"700_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nprot.2014.039","volume":"9","author":"E Pardon","year":"2014","unstructured":"Pardon, E., Laeremans, T., Triest, S., Rasmussen, S. G., Wohlk\u00f6nig, A., Ruf, A., et al. (2014). A general protocol for the generation of Nanobodies for structural biology. Nature Protocols, 9(3), 674\u2013693.","journal-title":"Nature Protocols"},{"issue":"11","key":"700_CR25","doi-asserted-by":"publisher","first-page":"e113688","DOI":"10.1371\/journal.pone.0113688","volume":"9","author":"I Jov\u010devska","year":"2014","unstructured":"Jov\u010devska, I., Zupanec, N., Ko\u010devar, N., Cesselli, D., Podergajs, N., Stokin, C. L., et al. (2014). TRIM28 and \u03b2-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers. PLoS ONE, 9(11), e113688.","journal-title":"PLoS ONE"},{"issue":"16","key":"700_CR26","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1158\/0008-5472.CAN-11-2994","volume":"72","author":"K Movahedi","year":"2012","unstructured":"Movahedi, K., Schoonooghe, S., Laoui, D., Houbracken, I., Waelput, W., Breckpot, K., et al. (2012). Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Research, 72(16), 4165\u20134177.","journal-title":"Cancer Research"},{"issue":"9","key":"700_CR27","first-page":"884","volume":"21","author":"F Ranjibar","year":"2018","unstructured":"Ranjibar, F., Habibi-Anbouhi, M., Kazemi-Lomedasht, F., Aghaee-Bakhtiyari, S. H., Alirahimi, E., & Behdani, M. (2018). Cell-specific targeting by engineered M13 bacteriophage expressing VEGFR2 nanobody. Iranian Journal of Basic Medical Sciences, 21(9), 884.","journal-title":"Iranian Journal of Basic Medical Sciences"},{"key":"700_CR28","first-page":"657","volume-title":"Affinity measurements by competition ELISA","author":"P Martineau","year":"2010","unstructured":"Martineau, P. (2010). Affinity measurements by competition ELISA (pp. 657\u2013665). Springer."},{"issue":"1\u20132","key":"700_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0022-1759(87)90187-6","volume":"100","author":"JD Beatty","year":"1987","unstructured":"Beatty, J. D., Beatty, B. G., & Vlahos, W. G. (1987). Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. Journal of Immunological Methods, 100(1\u20132), 173\u2013179.","journal-title":"Journal of Immunological Methods"},{"issue":"12","key":"700_CR30","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.4049\/jimmunol.168.12.5993","volume":"168","author":"BL Hsu","year":"2002","unstructured":"Hsu, B. L., Harless, S. M., Lindsley, R. C., Hilbert, D. M., & Cancro, M. P. (2002). Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. The Journal of Immunology, 168(12), 5993\u20135996.","journal-title":"The Journal of Immunology"},{"issue":"11","key":"700_CR31","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","volume":"48","author":"KP Baker","year":"2003","unstructured":"Baker, K. P., Edwards, B. M., Main, S. H., Choi, G. H., Wager, R. E., Halpern, W. G., et al. (2003). Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis & Rheumatism, 48(11), 3253\u20133265.","journal-title":"Arthritis & Rheumatism"},{"issue":"5","key":"700_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2506","volume":"10","author":"R Furie","year":"2008","unstructured":"Furie, R., Stohl, W., Ginzler, E. M., Becker, M., Mishra, N., Chatham, W., et al. (2008). Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Research & Therapy, 10(5), 1\u201315.","journal-title":"Arthritis Research & Therapy"},{"issue":"3","key":"700_CR33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang, F., Bae, S.-C., Bass, D., Chu, M., Egginton, S., Gordon, D., et al. (2018). A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Annals of the Rheumatic Diseases, 77(3), 355\u2013363.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7","key":"700_CR34","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/art.30372","volume":"63","author":"R Van Vollenhoven","year":"2011","unstructured":"Van Vollenhoven, R., Kinnman, N., Vincent, E., Wax, S., & Bathon, J. (2011). Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase II, randomized, placebo-controlled trial. Arthritis & Rheumatism, 63(7), 1782\u20131792.","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"700_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10072-010-0382-6","volume":"31","author":"V Bruno","year":"2011","unstructured":"Bruno, V., Battaglia, G., & Nicoletti, F. (2011). The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases. Neurological Sciences, 31(3), 283\u2013288.","journal-title":"Neurological Sciences"},{"issue":"12","key":"700_CR36","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzov\u00e1, D., et al. (2011). A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 63(12), 3918.","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"700_CR37","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/09612033211028653","volume":"30","author":"RA Levy","year":"2021","unstructured":"Levy, R. A., Gonzalez-Rivera, T., Khamashta, M., Fox, N. L., Jones-Leone, A., Rubin, B., et al. (2021). 10 Years of belimumab experience: What have we learnt? Lupus, 30(11), 1705\u20131721.","journal-title":"Lupus"},{"issue":"6428","key":"700_CR38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C., Atarhouch, T., Muyldermans, Sa., Robinson, G., Hammers, C., Songa, E. B., et al. (1993). Naturally occurring antibodies devoid of light chains. Nature, 363(6428), 446\u20138.","journal-title":"Nature"},{"issue":"1","key":"700_CR39","first-page":"1","volume":"3","author":"SM Moghimi","year":"2013","unstructured":"Moghimi, S. M., Rahbarizadeh, F., Ahmadvand, D., & Parhamifar, L. (2013). Heavy chain only antibodies: a new paradigm in personalized HER2+ breast cancer therapy. BioImpacts, 3(1), 1.","journal-title":"BioImpacts"},{"issue":"3","key":"700_CR40","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ijc.10212","volume":"98","author":"V Cortez-Retamozo","year":"2002","unstructured":"Cortez-Retamozo, V., Lauwereys, M., Hassanzadeh, Gh. G., Gobert, M., Conrath, K., Muyldermans, S., et al. (2002). Efficient tumor targeting by single-domain antibody fragments of camels. International Journal of Cancer, 98(3), 456\u2013462.","journal-title":"International Journal of Cancer"},{"issue":"11","key":"700_CR41","doi-asserted-by":"publisher","first-page":"e28218","DOI":"10.1371\/journal.pone.0028218","volume":"6","author":"G Hussack","year":"2011","unstructured":"Hussack, G., Hirama, T., Ding, W., MacKenzie, R., & Tanha, J. (2011). Engineered single-domain antibodies with high protease resistance and thermal stability. PLoS ONE, 6(11), e28218.","journal-title":"PLoS ONE"},{"issue":"3","key":"700_CR42","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1110\/ps.34602","volume":"11","author":"M Dumoulin","year":"2002","unstructured":"Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G., et al. (2002). Single-domain antibody fragments with high conformational stability. Protein Science, 11(3), 500\u2013515.","journal-title":"Protein Science"},{"issue":"1","key":"700_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/HAB-190390","volume":"28","author":"MA Mir","year":"2020","unstructured":"Mir, M. A., Mehraj, U., Sheikh, B. A., & Hamdani, S. S. (2020). Nanobodies: The \u201cmagic bullets\u201d in therapeutics, drug delivery and diagnostics. Human Antibodies, 28(1), 29\u201351.","journal-title":"Human Antibodies"},{"issue":"1","key":"700_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/abt\/tbaa003","volume":"3","author":"S Nie","year":"2020","unstructured":"Nie, S., Wang, Z., Moscoso-Castro, M., D\u2019Souza, P., Lei, C., Xu, J., et al. (2020). Biology drives the discovery of bispecific antibodies as innovative therapeutics. Antibody Therapeutics, 3(1), 18\u201362.","journal-title":"Antibody Therapeutics"},{"key":"700_CR45","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fonc.2020.01182","volume":"10","author":"EY Yang","year":"2020","unstructured":"Yang, E. Y., & Shah, K. (2020). Nanobodies: Next generation of cancer diagnostics and therapeutics. Frontiers in Oncology, 10, 1182.","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"700_CR46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/COC.0000000000000669","volume":"43","author":"V Jindal","year":"2020","unstructured":"Jindal, V., Khoury, J., Gupta, R., & Jaiyesimi, I. (2020). Current status of chimeric antigen receptor T-cell therapy in multiple myeloma. American Journal of Clinical Oncology, 43(5), 371\u2013377.","journal-title":"American Journal of Clinical Oncology"},{"issue":"5","key":"700_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10529-020-02823-2","volume":"42","author":"S Li","year":"2020","unstructured":"Li, S., Jiang, K., Wang, T., Zhang, W., Shi, M., Chen, B., et al. (2020). Nanobody against PDL1. Biotechnology letters, 42(5), 727\u2013736.","journal-title":"Biotechnology letters"},{"issue":"3","key":"700_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/mab.2016.0001","volume":"35","author":"F Kazemi-Lomedasht","year":"2016","unstructured":"Kazemi-Lomedasht, F., Behdani, M., Habibi-Anbouhi, M., & Shahbazzadeh, D. (2016). Production and characterization of novel camel single domain antibody targeting mouse vascular endothelial growth factor. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 35(3), 167\u2013171.","journal-title":"Monoclonal Antibodies in Immunodiagnosis and Immunotherapy"}],"container-title":["Molecular Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-023-00700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12033-023-00700-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-023-00700-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T04:17:43Z","timestamp":1699244263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12033-023-00700-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s12033-023-00700-7","relation":{},"ISSN":["1073-6085","1559-0305"],"issn-type":[{"value":"1073-6085","type":"print"},{"value":"1559-0305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"8 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}